Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acceptable risks in adjuvant therapy].

K W Brunner

    Onkologie
    |August 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Defining acceptable risks for adjuvant cancer therapies requires balancing benefits against side effects. Objective evaluation of cost-benefit relationships, based on clinical trials and micrometastasis detection, is crucial for informed medical and ethical decisions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation.

    Annals of oncology : official journal of the European Society for Medical Oncology·2003
    Same author

    ["primum nil nocere" and clinical cancer research. Observations on a controversy].

    Schweizerische medizinische Wochenschrift·1994
    Same author

    Present and future projects of the International Breast Cancer Study Group.

    Cancer·1994
    Same author

    Bioavailability and feasibility of subcutaneous 5-fluorouracil.

    British journal of cancer·1993
    Same author

    Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.

    Annals of oncology : official journal of the European Society for Medical Oncology·1993
    Same author

    Long-term toxicity and economic aspects: critical review.

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·1993
    Same journal

    Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

    Onkologie·2013
    Same journal

    Metastatic germ cell tumour following renal transplantation.

    Onkologie·2013
    Same journal

    miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.

    Onkologie·2013
    Same journal

    A meta-analysis of internal mammary lymph node metastasis in breast cancer patients.

    Onkologie·2013
    Same journal

    Patient-related delay in presentation for cutaneous squamous cell carcinoma. A cross-sectional clinical study.

    Onkologie·2013
    Same journal

    Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

    Onkologie·2013
    See all related articles

    Area of Science:

    • Oncology
    • Clinical Pharmacology
    • Medical Ethics

    Context:

    • Adjuvant therapies are crucial in cancer treatment, aiming to eliminate residual disease.
    • The evaluation of risks versus benefits in adjuvant therapy is complex and multifaceted.
    • Current limitations in detecting micrometastases hinder precise individual benefit assessment.

    Purpose:

    • To define acceptable risk parameters for adjuvant cancer therapies.
    • To emphasize the necessity of prospective clinical trials for benefit evaluation.
    • To highlight the importance of considering both short- and long-term side effects, including organ toxicity and secondary cancers.

    Summary:

    • Acceptable risk in adjuvant therapy hinges on a cost-benefit analysis, requiring prospective trials for each tumor type.

    Related Experiment Videos

  • Accurate benefit assessment is currently limited by the lack of micrometastasis detection methods.
  • Adjuvant treatments can be categorized by their efficacy (successful, promising, experimental, controversial, negative).
  • Risks encompass short-, medium-, and long-term side effects, with particular concern for organ toxicity and secondary malignancies.

    • Impact:

    • Informs clinical decision-making regarding the use of adjuvant therapies.
    • Guides the development of more precise risk-benefit assessment tools.
    • Promotes evidence-based and ethically sound practices in oncology.
    • Underscores the need for objective data over prejudice in defining treatment risks.